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Introduction
Biological therapy has dramatically improved the treat-
ment of patients with JIA. However, there is still a group
of patients that shows a lack of clinical response to this
treatment. The use of robust predictive markers of
response to identify individuals who are likely to respond
to etanercept may provide guidance in optimizing treat-
ment strategies.
Objectives
To test the ability of MRP8/14 serum levels to differentiate
between responders and non-responders to etanercept
before start of treatment, and to correlate longitudinal fol-
low-up of these markers with response to treatment.
Methods
Samples were collected from 71 JIA patients (43 polyarthri-
tis (12 RF positive), 18 extendend oligoarthritis, 3 persistent
oligoarthritis, 1 enthesitis related arthritis, 6 psoriatic
arthritis) included in the Dutch Arthritis and Biologics in
Children (ABC) Register treated with etanercept. The
patients were categorized into responders (acrpedi≥50)
(n = 55) and non-responders (acrpedi≤50) (n = 16) accord-
ing to the acrpedi response criteria and Wallace criteria of
disease activity. Serum concentrations of MRP8/14 com-
plexes were measured by ELISA at start of etanercept and
in 34 patients also after start of treatment. Non-parametric
tests were used to analyse the data.
Results
Before initiation of etanercept treatment, responders
showed significantly higher levels of MRP8/14 serum com-
plexes compared to non-responders (p < 0.001). Univariate
analysis showed no association between MRP8/14 and JIA
disease activity (JADAS10) at baseline. In non-responders
levels did not significantly change after initiation of treat-
ment whereas levels decreased in responders (p < 0.001).
Conclusion
High levels of baseline serum MRP8/14 have prognostic
value in predicting a subgroup of JIA patients who will
respond well to etanercept treatment. Decrease of MRP8/
14 after initiation of treatment is associated with response
to treatment.
Disclosure of interest
J. Anink: None declared., M. Otten Grant/Research Sup-
port from: Abbott, Novartis, Roche, Pfizer, Consultant for:
Roche, L. Van Suijlekom-Smit Grant/Research Support
from: Dutch Board of Health Insurances, Dutch Arthritis
Association, Pfizer, Abbott, Consultant for: Roche, Novar-
tis, M. Van Rossum: None declared., K. Dolman: None
declared., E. Hoppenreijs: None declared., R. Ten Cate
Grant/Research Support from: Pfizer, Consultant for:
Pfizer, T. Vogl: None declared., D. Foell: None declared.,
J. Roth: None declared., D. Holzinger Grant/Research
Support from: Pfizer.
1Paediatrics and Paediatric Rheumatology, Erasmus MC Sophia Children’s
Hospital, Rotterdam, Netherlands
Full list of author information is available at the end of the article
Anink et al. Pediatric Rheumatology 2013, 11(Suppl 2):P157
http://www.ped-rheum.com/content/11/S2/P157
© 2013 Anink et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Authors’ details
1Paediatrics and Paediatric Rheumatology, Erasmus MC Sophia Children’s
Hospital, Rotterdam, Netherlands. 2Paediatrics and Paediatric Rheumatology,
Academic Medical Centre and Reade Institute, Rotterdam, Netherlands.
3Paediatrics and Paediatric Rheumatology, St. Lucas Andreas Hospital and
Reade Institute, Amsterdam, Netherlands. 4Paediatrics and Paediatric
Rheumatology, St. Maartenskliniek and Radboud University Medical Centre,
Nijmegen, Netherlands. 5Paediatrics and Paediatric Rheumatology, Leiden
University Medical Centre, Leiden, Netherlands. 6Institute of Immunology,
University Hospital Muenster, Muenster, Germany. 7Germany Interdisciplinary
Centre for Clinical Research IZKF, University Hospital Muenster, Muenster,
Germany. 8Department of Paediatric Rheumatology and Immunology,
University Children’s Hospital Muenster, Muenster, Germany. 9Germany
Interdisciplinary Centre for Clinical Research IZKF, University of Muenster,
Muenster, Germany.
Published: 5 December 2013
doi:10.1186/1546-0096-11-S2-P157
Cite this article as: Anink et al.: PReS-FINAL-2145: MRP8/14 serum
complexes as predictor of response to etanercept treatment in juvenile
idiopathic arthritis. Pediatric Rheumatology 2013 11(Suppl 2):P157.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Anink et al. Pediatric Rheumatology 2013, 11(Suppl 2):P157
http://www.ped-rheum.com/content/11/S2/P157
Page 2 of 2
